Literature DB >> 19146746

Tuberculosis incidence among contacts of active pulmonary tuberculosis.

M Cailleaux-Cezar1, D de A Melo, G M Xavier, C L G de Salles, F C Q de Mello, A Ruffino-Netto, J E Golub, A Efron, R E Chaisson, M B Conde.   

Abstract

BACKGROUND: Treatment of latent tuberculosis (TB) infection (LTBI) in Brazil is recommended only in the case of contacts of pulmonary smear-positive TB patients aged<or=15 years with a tuberculin skin test (TST)>or=10 mm and no previous bacille Calmette-Guérin (BCG) vaccination or with a TST>or=15 mm regardless of previous BCG vaccination.
OBJECTIVE: To evaluate the 2-year incidence and predictors of TB among contacts who did not meet the Brazilian criteria for LTBI treatment.
DESIGN: Retrospective cohort study. Contacts aged between 12 and 15 years and those aged>or=15 years who did not meet the Brazilian criteria for LTBI treatment were enrolled in the study.
RESULTS: TB incidence was 3.2% (22/667), with an estimated TB rate of 1649 per 100000 population. Risk of TB was greater among the 349 contacts with TST>or=5 mm (5.4%) compared to the 318 contacts with TST<5 mm (0.9%; RR 6.04, 95%CI 1.7-20.6).
CONCLUSION: The high incidence of TB among contacts who did not meet the Brazilian criteria for LTBI treatment strongly suggests that these criteria should be reviewed. Furthermore, even among BCG-vaccinated contacts, TST induration>or=5 mm was the only variable that predicted the development of TB disease within 2years.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19146746      PMCID: PMC3713782     

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  12 in total

Review 1.  Targeted tuberculin testing and treatment of latent tuberculosis infection. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. This is a Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). This statement was endorsed by the Council of the Infectious Diseases Society of America. (IDSA), September 1999, and the sections of this statement.

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  2000-04       Impact factor: 21.405

Review 2.  Clinical practice. Latent tuberculosis infection.

Authors:  Robert M Jasmer; Payam Nahid; Philip C Hopewell
Journal:  N Engl J Med       Date:  2002-12-05       Impact factor: 91.245

3.  Preventive therapy of tuberculous infection.

Authors: 
Journal:  Am Rev Respir Dis       Date:  1974-09

4.  The prognosis of a positive tuberculin reaction in childhood and adolescence.

Authors:  G W Comstock; V T Livesay; S F Woolpert
Journal:  Am J Epidemiol       Date:  1974-02       Impact factor: 4.897

Review 5.  Controlled chemoprophylaxis trials in tuberculosis. A general review.

Authors:  S H Ferebee
Journal:  Bibl Tuberc       Date:  1970

6.  Long term isoniazid prophylaxis. Controlled trial on INH prophylaxis after recent tuberculin conversion in young adults.

Authors:  G J Veening
Journal:  Bull Int Union Tuberc       Date:  1968-12

7.  Outcomes of contact investigations of infectious tuberculosis patients.

Authors:  S M Marks; Z Taylor; N L Qualls; R J Shrestha-Kuwahara; M A Wilce; C H Nguyen
Journal:  Am J Respir Crit Care Med       Date:  2000-12       Impact factor: 21.405

8.  Treatment of latent tuberculosis infection in contacts of new tuberculosis cases in the United States.

Authors:  Mary R Reichler; Randall Reves; Sarah Bur; Josie Ford; Virginia Thompson; Bonita Mangura; Ida M Onorato; Sarah E Valway
Journal:  South Med J       Date:  2002-04       Impact factor: 0.954

9.  Evaluation of investigations conducted to detect and prevent transmission of tuberculosis.

Authors:  Mary R Reichler; Randall Reves; Sarah Bur; Virginia Thompson; Bonita T Mangura; Josie Ford; Sarah E Valway; Ida M Onorato
Journal:  JAMA       Date:  2002-02-27       Impact factor: 56.272

10.  Tuberculosis elimination in the countries of Europe and other industrialized countries.

Authors:  L Clancy; H L Rieder; D A Enarson; S Spinaci
Journal:  Eur Respir J       Date:  1991-11       Impact factor: 16.671

View more
  7 in total

1.  Community-randomized trial of enhanced DOTS for tuberculosis control in Rio de Janeiro, Brazil.

Authors:  S C Cavalcante; B Durovni; G L Barnes; F B A Souza; R F Silva; P F Barroso; C I Mohan; A Miller; J E Golub; R E Chaisson
Journal:  Int J Tuberc Lung Dis       Date:  2010-02       Impact factor: 2.373

Review 2.  Contact investigation for tuberculosis: a systematic review and meta-analysis.

Authors:  Gregory J Fox; Simone E Barry; Warwick J Britton; Guy B Marks
Journal:  Eur Respir J       Date:  2012-08-30       Impact factor: 16.671

3.  Vitamin D status and incidence of tuberculosis infection conversion in contacts of pulmonary tuberculosis patients: a prospective cohort study.

Authors:  A Arnedo-Pena; J V Juan-Cerdán; M A Romeu-García; D García-Ferrer; R Holguín-Gómez; J Iborra-Millet; F Pardo-Serrano
Journal:  Epidemiol Infect       Date:  2014-10-02       Impact factor: 4.434

4.  HIV-1 infection impairs the bronchoalveolar T-cell response to mycobacteria.

Authors:  Barbara Kalsdorf; Thomas J Scriba; Kathryn Wood; Cheryl L Day; Keertan Dheda; Rodney Dawson; Willem A Hanekom; Christoph Lange; Robert J Wilkinson
Journal:  Am J Respir Crit Care Med       Date:  2009-09-24       Impact factor: 21.405

5.  Sex bias in infectious disease epidemiology: patterns and processes.

Authors:  Felipe Guerra-Silveira; Fernando Abad-Franch
Journal:  PLoS One       Date:  2013-04-24       Impact factor: 3.240

6.  Impact of latent infection treatment in indigenous populations.

Authors:  Lucia Suemi Yuhara; Flávia Patussi Correia Sacchi; Julio Croda
Journal:  PLoS One       Date:  2013-07-31       Impact factor: 3.240

7.  Predicting the artificial immunity induced by RUTI® vaccine against tuberculosis using universal immune system simulator (UISS).

Authors:  Marzio Pennisi; Giulia Russo; Giuseppe Sgroi; Angela Bonaccorso; Giuseppe Alessandro Parasiliti Palumbo; Epifanio Fichera; Dipendra Kumar Mitra; Kenneth B Walker; Pere-Joan Cardona; Merce Amat; Marco Viceconti; Francesco Pappalardo
Journal:  BMC Bioinformatics       Date:  2019-12-10       Impact factor: 3.169

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.